460 related articles for article (PubMed ID: 20100187)
1. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
2. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
3. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
4. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
[TBL] [Abstract][Full Text] [Related]
5. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
[TBL] [Abstract][Full Text] [Related]
6. Mastocytosis and insect venom allergy.
Bonadonna P; Zanotti R; Müller U
Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):347-53. PubMed ID: 20485157
[TBL] [Abstract][Full Text] [Related]
7. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy against hymenoptera venom: report of ten patients].
Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
[TBL] [Abstract][Full Text] [Related]
9. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.
Lerch E; Müller UR
J Allergy Clin Immunol; 1998 May; 101(5):606-12. PubMed ID: 9600496
[TBL] [Abstract][Full Text] [Related]
10. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
[TBL] [Abstract][Full Text] [Related]
11. Hymenoptera venom immunotherapy and field stings.
Lang R; Hawranek T
J Investig Allergol Clin Immunol; 2006; 16(4):224-31. PubMed ID: 16889279
[TBL] [Abstract][Full Text] [Related]
12. The sting challenge test in Hymenoptera venom allergy: pros and cons.
Bilò MB; Brianzoni MF; Garritani MS; Antonicelli L; Farabollini B; Bonifazi F
Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):377-81. PubMed ID: 14768522
[TBL] [Abstract][Full Text] [Related]
13. Serum tryptase level is a better predictor of systemic side effects than prostaglandin D2 metabolites during venom immunotherapy in children.
Cichocka-Jarosz E; Sanak M; Szczeklik A; Brzyski P; Gielicz A; Pietrzyk JJ
J Investig Allergol Clin Immunol; 2011; 21(4):260-9. PubMed ID: 21721371
[TBL] [Abstract][Full Text] [Related]
14. Possible circadian variation of serum mast cell tryptase concentration.
Dugas-Breit S; Przybilla B; Schöpf P; Ruëff F
Allergy; 2005 May; 60(5):689-92. PubMed ID: 15813817
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome after venom immunotherapy.
Golden DB
Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):337-41. PubMed ID: 20610978
[TBL] [Abstract][Full Text] [Related]
16. Gene expression analysis in predicting the effectiveness of insect venom immunotherapy.
Niedoszytko M; Bruinenberg M; de Monchy J; Wijmenga C; Platteel M; Jassem E; Oude Elberink JN
J Allergy Clin Immunol; 2010 May; 125(5):1092-7. PubMed ID: 20334904
[TBL] [Abstract][Full Text] [Related]
17. Hymenoptera venom allergy.
Przybilla B; Ruëff F
J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
[TBL] [Abstract][Full Text] [Related]
18. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
19. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
20. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Körner M; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B
J Allergy Clin Immunol; 2009 Nov; 124(5):1047-54. PubMed ID: 19895993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
